of aminoglutethimide (AG) on androgen and estrogen levels estrone ([EJ], estradiol [E2], plasma dehydro-epiandrosterone-sulfate [DHEA-S], testosterone [T], dihydrotestosterone [DHT], A4-androstenedione [A4-A]), follicle-stimulating hormone (FSH), luteinizing hor-mone (LH), and prolactin in postmenopausal patients with breast cancer randomly allocated to either AG treatment or bilateral surgical adrenalectomy as a control group. In response to either treatment, the plasma levels of El fell 62-75 % (P < 0.001) and urine El 85.7-88.7 % (P <0.001) in all study days over a 12-wk period. Similarly, the concentrations of E2 in plasma and urine fell 40-72 % without statistically significant differences between the two treatment modalities. The relatively weak androgen, DHEA-S, was re-duced by 92 % (877.3±184.6 to 71.8±14.5 ng/ml) at 12 wk in women treated with AG, but suppressed nearly 99 % (1,151+262 to 5.8±3.3 ng/ml) in adrenalectomized women. At all time points after treatment, the DHEA-S levels were significantly higher in patients receiving AG. Plasma concentrations of the potent androgens, T and DHT, were also relatively preserved during AG treatment. T levels were never significantly reduced by AG, and DHT concentrations were decreased only at the 4th wk to a maximum of 20%. A4-A levels fell 56 % in response to this drug only on the 12th wk o
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.